Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT ID: NCT06729593
Last Updated: 2025-10-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
87 participants
INTERVENTIONAL
2021-04-20
2022-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
NCT04745351
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780541
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780281
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
NCT04292899
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT04843761
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This protocol will be adaptive, randomized, blinded and initially placebo-controlled. Participants will receive standard of care (SOC) treatment as part of the protocol.
This protocol will be conducted in up to several hundred clinical sites. Participating sites are affiliated with networks funded by the United States National Institutes of Health (NIH) and the US Department of Veterans Affairs.
The protocol is for a Phase 3 study.
Participants will be followed for 90 days following randomization for the primary endpoint and most secondary endpoints. Selected secondary endpoints will be measured at 180 days.
This study is planned to provide 80% power to detect an odds ratio of 1.5 for improvement in recovery status at Day 90 for Remdesivir versus placebo with use of the ordinal outcome. The planned sample size is 320 participants. Sample size may be re-estimated before enrollment is complete based on an assessment of whether the pooled proportions of the outcome are still consistent with adequate power for the hypothesized difference measured by the odds ratio.
Randomization will be stratified by study site pharmacy and by receipt of invasive mechanical ventilation, or ECMO (extracorporeal membrane oxygenation) at enrollment. Other agent-specific stratification factors may be considered.
An independent Data and Safety Monitoring Board (DSMB) will review interim safety and efficacy data at least monthly. Pre-specified guidelines will be established to recommend early stopping of the trial for evidence of harm or substantial efficacy. The DSMB may recommend discontinuation of an investigational agent if the risks are judged to outweigh the benefits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remdesivir + SOC
Remdesivir
Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
Corticosteroid
In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Placebo + SOC
Remdesivir Placebo
Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Corticosteroid
In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remdesivir
Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
Remdesivir Placebo
Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Corticosteroid
In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Prior receipt of any dose of remdesivir during the present illness
* GFR (glomerular filtration rate) \< 30 ml/min and not receiving dialysis
* ALT (alanine aminotransferase) or AST (aspartate aminotransferase) \> 10 times upper limit of normal
* Unwillingness to commit to avoid sex that may result in pregnancy for at least 7 days after completion of remdesivir vs. placebo
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
NETWORK
University of Copenhagen
OTHER
Medical Research Council
OTHER_GOV
Kirby Institute
OTHER_GOV
Washington D.C. Veterans Affairs Medical Center
FED
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK
US Department of Veterans Affairs
FED
Prevention and Early Treatment of Acute Lung Injury (PETAL) Network
UNKNOWN
Gilead Sciences
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuel Brown, MD
Role: PRINCIPAL_INVESTIGATOR
Intermountain Medical Center/University of Utah
Prof. James Neaton
Role: STUDY_CHAIR
INSIGHT Statistical and Coordinating Centre, University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue
Tucson, Arizona, United States
UCSF Fresno (Site 203-005), 155 N. Fresno Street
Fresno, California, United States
VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street
Loma Linda, California, United States
Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Boulevard
Los Angeles, California, United States
Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza
Los Angeles, California, United States
UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St.
San Francisco, California, United States
UCSF Medical Center (Site 203-001), Moffit-Long Hospital, 505 Parnassus Ave.
San Francisco, California, United States
Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr.
Stanford, California, United States
University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue
Aurora, Colorado, United States
Denver Health Medical Center (Site 204-004), 780 Delaware Street, Pavilion B
Denver, Colorado, United States
MedStar Health Research Institute (Site 009-021), 110 Irving St., NW.
Washington D.C., District of Columbia, United States
Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW.
Washington D.C., District of Columbia, United States
Emory University (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE.
Atlanta, Georgia, United States
Massachusetts General Hospital (Site 202-002), 55 Fruit Street
Boston, Massachusetts, United States
Baystate Medical Center (Site 201-001), Critical Care Research, 759 Chestnut Street
Springfield, Massachusetts, United States
Mount Sinai Medical Center (Site 301-012), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place
New York, New York, United States
Columbia University Irving Medical Center (Site 301-027), 177 Fort Washington Ave.
New York, New York, United States
Montefiore Medical Center - Moses Hospital (Site 206-001), 111 E. 210th Street
The Bronx, New York, United States
Montefiore Medical Center - Weiler campus (Site 206-003), 111 E. 210th Street
The Bronx, New York, United States
Duke University Hospital (Site 301-006), 2301 Erwin Road
Durham, North Carolina, United States
Wake Forest Baptist Health (Site 210-001), Medical Center Blvd
Winston-Salem, North Carolina, United States
University of Cincinnati Medical Center (Site 207-003), 234 Goodman Street, ML 0740
Cincinnati, Ohio, United States
Cleveland Clinic Fairview Hospital (Site 207-005), 18101 Lorain Ave.
Cleveland, Ohio, United States
Cleveland Clinic Foundation (Site 207-001), 9500 Euclid Ave.
Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center (Site 207-004), 410 W. 10th Avenue
Columbus, Ohio, United States
Cleveland Clinic Marymount Campus (Site 207-006), 12300 McCracken Road
Garfield Heights, Ohio, United States
Cleveland Clinic Hillcrest Hospital (Site 207-007), 6780 Mayfield Road
Mayfield Heights, Ohio, United States
Oregon Health & Science University (Site 208-003), 3181 SW Sam Jackson Park Rd.
Portland, Oregon, United States
Medical University of South Carolina (Site 210-002), 96 Jonathan Lucas St., CSB 214
Charleston, South Carolina, United States
Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive
Nashville, Tennessee, United States
Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave.
Dallas, Texas, United States
Houston Methodist Hospital (Site 301-028), 6565 Fannin Street
Houston, Texas, United States
Texas Heart Institute (Site 301-017), 6770 Bertner, MC4-266
Houston, Texas, United States
University of Texas Health Science Center (Site 203-006), 7000 Fannin St.
Houston, Texas, United States
Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street
Murray, Utah, United States
University of Utah Hospital (Site 211-002), 50 North Medical Drive
Salt Lake City, Utah, United States
UVA School of Medicine (Site 210-003), University of Virginia Health System, University Hospital, 1215 Lee St.
Charlottesville, Virginia, United States
Harborview Medical Center (Site 208-001), 325 9th Ave.
Seattle, Washington, United States
Swedish Medical Center (Site 208-005), 747 Broadway
Seattle, Washington, United States
West Virginia University Medicine (Site 301-023), One Medical Center Drive
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol: Remdesivir (H2)
Document Type: Study Protocol: Master
Document Type: Study Protocol: Aviptadil (H1)
Document Type: Study Protocol: Trial Document Overview
Document Type: Statistical Analysis Plan: Addendum
Document Type: Statistical Analysis Plan: Main
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
CDC (Centers for Disease Control and Prevention): Coronavirus (COVID-19) website
A Participant's Guide to Clinical Trials (NIAID)
Find a Clinical Trial (NIAID)
Clinical Trials at NIAID
National Institute for Allergy and Infectious Diseases (NIAID)
WHO COVID-19 treatment guidelines
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
015/ACTIV-3b/H2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.